However, when depleting CD4+ or CD8+ T cells before rechallenge with a second MMRd tumor, we observed that CD4+ depletion did not change the percentage of engraftment, while CD8+ T cell depletion led to a 100% engraftment rate, indicating that specific and shared anti-tumor immune memory is primarily driven by CD8+ T cells (Figure 2 D). The gene discussed is CD8A; the disease is neoplasm.